Skip to main content

Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products

February 23, 2021

“AbbVie and Caribou Biosciences, Inc have announced that the companies have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR) T-cell therapeutics.”

AbbVie and Caribou Team Up On Next-Gen Off-the-Shelf CAR-T Therapies

February 18, 2021

“AbbVie and Caribou are partnering to develop next-generation off-the-shelf CAR-T therapies for oncology indications. The collaboration centres around Caribou’s chRDNA technology to overcome challenges facing existing off-the-shelf CAR-T therapies.”

AbbVie, Caribou Biosciences Collaborate in $40 Million CAR-T Cell Deal

February 10, 2021

“AbbVie announced its latest chimeric antigen receptor (CAR)-T cell investment, a collaboration with Caribou Biosciences worth $40 million up front in cash and equity to develop two CRISPR-edited cell therapies against AbbVie-specified targets. AbbVie committed up to another $300 in potential milestone payments.”

CRISPR Technology: Where Female Entrepreneurs Thrive

March 8, 2020

“It wasn’t until Rachel Haurwitz was riding the subway to an attorney’s office in San Francisco to sign papers that she realized the enormousness of what she was doing–cofounding a biotech company.”

Harnessing Type I CRISPR-Cas Systems for Genome Engineering in Human Cells

November 19, 2019

Using a FokI fusion design, we show that Type I CRISPR-Cas systems can be expressed, reconstituted, and faithfully trafficked to the nucleus for genome engineering in human cells.